We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kedem Pharmaceuticals Signs Contract with Corealis Pharma
News

Kedem Pharmaceuticals Signs Contract with Corealis Pharma

Kedem Pharmaceuticals Signs Contract with Corealis Pharma
News

Kedem Pharmaceuticals Signs Contract with Corealis Pharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kedem Pharmaceuticals Signs Contract with Corealis Pharma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kedem Pharmaceuticals Inc. has announced that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company’s second lead therapeutic drug.

The KDM-1102 drug is a new sublingual formulation of propanolol. The formulation development of the KDM-1102 drug is now completed and can be produce in large volume.

“We are pleased with the progress we have been making in our development program on KDM-1102, our Second lead therapeutic drug for cardiovascular and anxiety attacks”, said Dr. Hassan Salari, Kedem Pharmaceuticals, President & CEO.

Advertisement